China cardiovascular system drugs industry market demand forecast and investment strategy planning, 2012 2016

China Cardiovascular System Drugs Industry Market Demand Forecast and Investment Strategy
Planning, 2012-2016
By Qianzhan Intelligence
Website: http://en.qianzhan.com/
Tel:+86 0755 33220413
Email us: carter@qianzhan.com.cn
With the improvement of people’s living standard, the acceleration of
population aging, and the fast pace of life, people tend to eat more high
calorie food and high-fat diet food, which will easily trigger the one of
the most serious diseases, named cardiovascular diseases which will
threaten our health and life, such as coronary disease, hypertension, and
cardiac failure. Moreover, its morbidity and mortality rate rise year after
year. Nowadays, the cardiovascular disease has become one of scariest
diseases threatening people’s life in the world, whose morbidity and
mortality rate jump to the top in the world. Therefore, this field is
regarded as one of markets with most development potentials.
There is huge demand and prospects for cardiovascular drugs market.
However, as to domestic market, a great many of market shares are
occupied by leading international pharmaceutical brands or their
subsidiaries, so the domestic pharmaceutical corporations need
improving their R&D level and market capacity.
With Forward’s long-term tracking and collecting market data of
cardiovascular system drugs industry, we roundly and accurately
analyze the industry structure system for you from the view of mastering
the whole industry. This report analyzes the impact of current economic,
social and policy environment on the industry; moreover, from aspect of
internal industry, it analyzes the market competition situation of
cardiovascular pharmaceutical chemicals and traditional Chinese
medicines for heart attack, and anti-hypertension in a systematic and
specific way. This report will show you the competition situation of
whole industry’s market with specific and objective data as well as
plenty of evidence.
The most distinctive characteristics of this report is forward-looking and
timeliness. Based on future development tracks and years’ practice
experience of cardiovascular system drugs industry, we conduct
objective and profound analysis on overall capacity, market size,
competitive landscape and market demand features of China
cardiovascular system drugs industry. In addition, based on future
development tracks and years’ practice experience of cardiovascular

system drugs industry, we conduct prudent analysis and forecast for
cardiovascular system drugs industry’s future development trend. This
report helps pharmaceutical corporations, R&D institutions, marketing
enterprises and investment enterprises to precisely grasp current latest
developments of the industry. This report is a first professional report on
providing the industry with segment research for cardiovascular drugs
and illustrating the competitive landscape from multiple
perspectives.
Here, we would like to express our sincere gratitude to China
Pharmaceutical Profession Association, Ministry of State Information
Center, Bureau of Statistics of China, International Information Research
Institute, Chinese Academy of International Trade and Economic
Cooperation, Tsinghua University Library, Development Research
Center of the State Council and Beijing Essence Forward Research
Center, for their great support when we conduct this report!
Notice: All the market data, especially corporations' ranking data in the
report, only for business reference. Please do not take the data for
enterprise publicity. Thank you! Or Forward shall not take any
responsibility for any consequences!
Special tips: Ignoring some subtle hints in the violent change of external
environment, and failure of updating strategic decisions timely will
finally lead to the loss of competitive advantage. A true successful
company will make scientific researches on external environment
consciously or unconsciously, so as to formulate a key scientific
operating strategy!
Best wishes for every enterprise with a big dream that can draw up a
high-quality operating decision, to effectively avoid the risks and
continuously gain the success.
Forward Business Intelligence Co., Ltd. Industry Research Center
Research Team of Cardiovascular System Drugs Industry
第 1 章：Overview of China Cardiovascular System Drugs Industry
1.1 Prevalence of Cardiovascular Diseases in China
1.1.1 Cardiovascular Disease and Classification
1.1.2 Patients and Death
1. Total Patients
2. Death Toll
1.1.3 Risks for Cardiovascular Disease
1. High Blood Pressure
2. Smoking

3. Dyslipidemia
4. Others
1.1.4 Medical Treatment for Cardiovascular Disease
1.2 Overview of Cardiovascular System Drugs Industry
1.2.1 Definition of Cardiovascular System Drugs Industry
1.2.2 Research Scope for Cardiovascular System Drugs Industry
1.2.3 Analytical Systems for Cardiovascular System Drugs Industry
第 2 章： Development Environment for China Cardiovascular System
Drugs Industry
2.1 Economic Conditions’ Impact on the Development of Industry
2.1.1 International Macro-economic Environment
1. International Macro-economic Status
2. International Macro-economic Outlook
2.1.2 Domestic Macro-economic Environment
1. Domestic Macro-economic Status
2. Domestic Macro-economic Outlook
2.1.3 Macro-economic Environment’s Impact on the Development of
Industry
2.2 Social Considerations’ Impact on the Development of Industry
2.2.1 Social Considerations Associated with Cardiovascular Disease
2.2.2 Social Considerations’ Impact on the Development of Industry
2.3 Policies’ Impact on the Development of Industry
2.3.1 Explanation of Policies Related to Industry Development
2.3.2 Explanation of Regulations Related to Industry Development
2.3.3 Policies’ Impact on the Development of Industry
第 3 章： Analysis of Market Status of Cardiovascular System Drugs
Industry
3.1 Development Overview of International Cardiovascular System
Drugs Market
3.1.1 Market Scale
3.1.2 Competitive Landscape
3.1.3 R&A Situation of International Pharmaceutical Corporations in
China
3.1.4 Development Trend
3.2 Development Status of Domestic Cardiovascular System Drugs
Industry
3.2.1 Market Features
3.2.2 Market Scale
3.2.3 Competitive Landscape in Major Cities
3.2.4 Competition Position for Major Manufacturers
第 4 章： Analysis of Pharmaceutical Chemicals Competition for
Cardiovascular System in China
4.1 Overview of Cardiovascular Pharmaceutical Chemicals Market
4.1.1 Overview of Pharmaceutical Chemicals Market

4.1.2 Size of Pharmaceutical Chemicals Market
4.1.3 Competitive Landscape for Drug Segments
4.1.4 Competitive Landscape for Regional Markets
4.2 Analysis of Cardiac drugs Market
4.2.1 Drugs and Market Overview
4.2.2 Market Size and Change Trend
4.2.3 Competitive Position for Manufacturers
4.2.4 Competitive Landscape for Drugs Market
4.2.5 Analysis of Major Drugs Market
1. Alprostadil
2. Phosphocreatine
3. Coenzyme Complex
4. Isosorbide Dinitrate
4.3 Analysis of Vasodilator Drugs Market
1. Cinepazide
2. Drochloride and Glucose Injection
3. Fasudil
4. 3-n-butylphthalide
5. Ligustrazine
4.4 Analysis of ACE inhibitor Market
1. Valsartan
2. Irbesartan
3. Losartan
4. Telmisartan
5. Benazepril
4.5 Analysis of Calcium Channel Blocker Market
1. Amlodipine
2. Nifedipine
3. Felodipine

4. Amlodipine
5. Nimodipine
4.6 Analysis of Antilipemic Agents Market
1. Atorvastatin
2. Simvastatin
3. Rosuvastatin
4. Pravastatin
4.7 Analysis of Beta Blocking Agent Market
1. Bisoprolol
2. Metoprolol
3. Potassium Magnesium Aspartate
4. Esmolol
5. Arotinolol
4.8 Analysis of Vascular Protective Agents Market
1. Invertose
2. Calcium Dobesilate
3. Diosmin
4. Troxerutin
4.9 Analysis of Antihypertensive Drug Market
1. Urapidil
2. Doxazosin
3. Nitroprusside
4.10 Diuretics

1. Torasemide
2. Indapamide
3. Spironolactone
4. Furosemide
第 5 章：Analysis of Cardiovascular System Drugs Market
5.1 Market Overview of Cardiovascular System Drug
5.2 Competitive Position for Cardiovascular System Drug Manufacturers
5.3 Competitive Landscape of Cardiovascular System Drugs
5.4 Analysis of Major Cardiovascular System Drugs
5.4.1 Ginkgo Injection
1. Brief Introduction to the Drug
2. Competitive Position for Major Manufactures
3. Competitive Landscape for Regional Drugs Market
4. Demand Trend for Drugs Market
5.4.2 Danhong Injection
5.4.3 Danshen Ligustrazine Injection
5.4.4 Ginkgo Biloba Tablet
5.4.5 Carthamus Tinctorius Injection
5.4.6 Shenmai Injection
第 6 章： Analysis of Leading Corporations in Cardiovascular System

Drugs Industry
6.1 Overall Situation of Cardiovascular System Drugs Manufacturers
6.1.1 Comprehensive Overview of Cardiovascular System Drugs
Manufacturers
6.1.2 Ranking of Cardiovascular System Drugs Manufacturers by Sales
Revenue
6.1.3 Ranking of Cardiovascular System Drugs Manufacturers by Total
Profits
6.2 Leading Global Cardiovascular System Drugs Brands’ Investment in
China
6.2.1 Pfizer
1. Development Overview
2. Sales Network
3. Product Structure
4. Operation Situation
5. Operation of Pfizer Dalian Plant
6.2.2 Novartis
2. Sales Network
5. Operation of Beijing Novartis Pharma Ltd.
6.2.3 Merck & Co., Inc.
2. Sales Network
5. Operation of Hangzhou Moshadong Pharmaceutical Co., Ltd.
6.2.4 Sanofi
2. Sales Network
5. Operation of Shenzhen Sanofi Pasteur Biological Products Co.,
Ltd.
6.2.5 Roche Holding Ltd.
2. Sales Network
5. Operation of Shanghai Roche Pharmaceutical Ltd.
6.2.6 Glaxo Smith Kline
2. Sales Network

5. Operation of Shanghai Glaxosmithkline Biological Products Co.,
Ltd.
6.2.7 AstraZeneca
2. Sales Network
5. Corporate Latest Trend
6.2.8 Bristol-Myers Squibb
2. Sales Network
5. Operation of Sino-American Shanghai Squibb Pharmaceuticals
Ltd.
6.2.9 Boehringer Ingelheim
2. Sales Network
5. Operation of Boehringer Ingelheim Shanghai Pharmaceuticals
Co., Ltd.
6.3 Case Study of Leading Corporations in Domestic Cardiovascular
System Drugs Industry
6.3.1 Beijing SL Pharmaceutical Co., Ltd.
1. Overall Development Information
2. Product and Market Positioning
3. Regional Market Distribution
4. Cardiovascular Drugs Market
5. Overall Operation
6. Operational Strengths and Weakness
7. Investment M&A
8. Latest Development Trend
6.3.2 Shenzhen Salubris Pharmaceuticals Co., Ltd.
7. Investment M&A

6.3.3 Tasly Pharmaceutical Group Co., Ltd.
7. Investment M&A
6.3.4 Taiantang Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.5 Guizhou Yibai Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.6 Beijing Tide Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.7 Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd.
7. Investment M&A

6.3.8 Haikou Qili Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.9 Xi’an Lijun Jinghua Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.10 Nanjing Hicin Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.11 Zhejiang Chengyi Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.12 Beijing Four Rings Bio-pharmaceutical Co., Ltd.

7. Investment M&A
6.3.13 Sichuan US-le-Grand Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.14 Yangtze River Pharmaceutical Group
7. Investment M&A
6.3.15 Shanghai Changzheng Fumin Jinshan Pharmaceutical Co.,
Ltd.
7. Investment M&A
6.3.16 Qilu Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.17 Zhejiang Hisun Pharmaceutical Co., Ltd.

7. Investment M&A
6.3.18 Shandong Buchang Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.19 Shijiazhuang Yiling Pharmaceutical Co., Ltd.
7. Investment M&A
6.3.20 China Shineway Pharmaceutical Group Limited
7. Investment M&A
第 7 章： Analysis of Development Trend and Prospects for China
Cardiovascular System Drugs Industry
7.1 Overall Competition of Industry
7.2 Competition Background of Industry – Both Opportunity and
Challenge
7.2.1 Development Opportunity for Industry
1. Relevant Polices Stimulates the Development of Industry
2. Market Cognition
7.2.2 Challenge Confronted by Industry Development
1. Overall Innovation Level of Industry
2. Corporate Size and Competition Strategy for Industry
3. Gap between Market Regulations and International Regulations
4. Staff Training and Technology Transfer Model

7.3 Competition Situation among the Industry – by Fierce
7.3.1 New Entrants
7.3.2 Fierce Internal Competition
7.3.3 Substitute Risk
7.3.4 Bargaining Power of Supplier and Buyer
7.4 Prospects and Forecast for Industry
7.4.1 Development Prospects
7.4.2 Development Trend
7.4.3 Investment Suggestion

China cardiovascular system drugs industry market demand forecast and investment strategy planning, 2012 2016

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (6)

Destaque

Destaque (19)

Semelhante a China cardiovascular system drugs industry market demand forecast and investment strategy planning, 2012 2016

Semelhante a China cardiovascular system drugs industry market demand forecast and investment strategy planning, 2012 2016 (20)

Mais de Qianzhan Intelligence

Mais de Qianzhan Intelligence (20)

Último

Último (20)

China cardiovascular system drugs industry market demand forecast and investment strategy planning, 2012 2016